DAIICHI SANKYO COMPANY, LIMITED Inactive Instrument
Daiichi Sankyo Company, Limited Stock Other OTC
Equities
DSNKY
US23381D1028
Pharmaceuticals
| Sales 2024 | 1,602B 10.11B 13.82B | Sales 2025 * | 1,761B 11.12B 15.2B | Capitalization | 9,607B 60.65B 82.9B |
|---|---|---|---|---|---|
| Net income 2024 | 201B 1.27B 1.73B | Net income 2025 * | 186B 1.17B 1.6B | EV / Sales 2024 | 5.72 x |
| Net cash position 2024 * | 556B 3.51B 4.8B | Net cash position 2025 * | 455B 2.87B 3.93B | EV / Sales 2025 * | 5.2 x |
| P/E ratio 2024 |
45.6
x | P/E ratio 2025 * |
49
x | Employees | - |
| Yield 2024 |
1.05% | Yield 2025 * |
1.14% | Free-Float | 97.04% |
More Fundamentals
* Assessed data
More news
Latest transcript on Daiichi Sankyo Company, Limited
More recommendations
More press releases
More news
| Managers | Title | Age | Since |
|---|---|---|---|
Sunao Manabe
CEO | Chief Executive Officer | 69 | 07-03-31 |
Hiroyuki Okuzawa
PSD | President | 61 | 17-03-31 |
Ken Takeshita
CTO | Chief Tech/Sci/R&D Officer | - | 21-03-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Sawako Nohara
BRD | Director/Board Member | 66 | 19-05-31 |
Kazuaki Kama
BRD | Director/Board Member | 75 | 19-05-31 |
Sunao Manabe
CEO | Chief Executive Officer | 69 | 07-03-31 |
Daiichi Sankyo Company specializes in developing, manufacturing and marketing pharmaceutical products. Net sales break down by activity as follows:
- sale of medicines (99.8%): prescription medicines (92.8% of net sales) and OTC medicines (7.2%) primarily for the treatment of thrombotic disorders, tumors, diabetes and rheumatoid arthritis;
- other (0.2%): primarily real estate activities.
Net sales are distributed geographically as follows: Japan (64.1%), North America (17.2%), Europe (9.7%) and other (9%).
Sector
Pharmaceuticals
Calendar
2024-07-30
- Q1 2024 Earnings Release (Projected)
Related indices
| 1st Jan change | Capi. | |
|---|---|---|
| +25.83% | 661B | |
| +27.00% | 566B | |
| -6.76% | 352B | |
| +20.34% | 332B | |
| +3.00% | 283B | |
| +13.09% | 231B | |
| +5.46% | 200B | |
| -9.61% | 195B | |
| -6.26% | 145B |
